Company profile for Kelonia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for soli...
Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Boston, Massachusetts
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

PEGS Boston Summit

PEGS Boston Summit

Not Confirmed

envelop Contact Supplier

PEGS Boston Summit

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260531412768/en/Kelonia-Therapeutics-Presents-Updated-First-in-Human-Data-from-Phase-1-inMMyCAR-Study-of-KLN-1010-in-vivo-BCMA-CAR-T-Therapy-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting

BUSINESSWIRE
31 May 2026

https://www.prnewswire.com/news-releases/lilly-to-showcase-oncology-portfolio-across-tumor-types-and-treatment-modalities-at-the-2026-american-society-of-clinical-oncology-annual-meeting-302778035.html

PR NEWSWIRE
22 May 2026

https://www.biospace.com/press-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies

BIOSPACE
21 Apr 2026

https://endpoints.news/kelonia-investor-venrock-will-clear-a-45-fold-return-on-startups-sale-to-lilly/

ENDPOINTS
20 Apr 2026

https://www.pharmiweb.com/press-release/2026-01-07/kelonia-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-kln-1

PHARMIWEB
07 Jan 2026

https://www.pharmiweb.com/press-release/2025-12-09/kelonia-therapeutics-presents-first-in-human-data-from-phase-1-inmmycar-study-of-kln-1010-in-vivo-bc

PHARMIWEB
09 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty